Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials

Table 1

Inclusion and exclusion criteria.

Domain	Inclusion criteria	Exclusion criteria
Population	Population of both chronic CAD or PAD patients	Children and adolescents (<18 years old); Studies evaluated only patients with CAD; Studies evaluated only patients with PAD
Interventions	(i) Xaban/direct thrombin inhibitors (rivaroxaban, dabigatran, apixaban, edoxaban, betrixaban); (ii) Antiplatelet (ASA, clopidogrel, ticagrelor, ticlopidine, triflusal, and prasugrel); (iii) Dipyridamole; (iv) Cilostazol; (v) Vorapaxar; (vi) Parenteral anticoagulants (low molecular weight heparin, unfractionated heparin, fondaparinux); (vii) Vitamin K antagonists (not limited to warfarin)
Comparators	Interventions + placebo
Outcomes of interest	Efficacy including: (i) Composite outcomes: (a) Stroke/MI/CV death; (b) CHD death/MI/IS/ALI; (c) CV death/MI/IS/ALI; (ii) Individual components of composite outcomes; (iii) All-cause mortality; (iv) Amputations; (v) HF; (vi) Unstable angina; (vii) Revascularisation; (viii) Bypass graft failure (occlusion); (ix) Stent thrombosis; (x) MALE; (xi) Venous thromboembolism; (xii) Haemorrhagic stroke; (xiii) Chronic limb ischaemia
	Safety including: (i) Major or severe bleeding; (ii) Fatal bleeding; (iii) Intracranial bleeding; (iv) Bleeding requiring re-operation; (v) Bleeding requiring hospitalisation; (vi) Total serious AEs; (vii) Total severe AEs; (viii) Gastrointestinal bleeding; (ix) Discontinuations (any, due to AEs)
Study design	Study type: (i) RCTs; (ii) Extensions of RCTs	Study type: (i) Review; (ii) Opinion, editorial, letter
Publication type	Full-text papers,

AEs: adverse events; ALI: acute limb ischaemia; CAD: coronary artery disease; CV: cardiovascular; HF: heart failure; IS: ischaemic stroke; MALE: major adverse limb events; MI: myocardial infarction; PAD: peripheral artery disease; RCT: randomised controlled trial; ASA: acetylsalicylic acid.